Researchers compared the monoclonal immunoglobulin rapid accurate measurement and matrix-assisted laser desorption/ionization-time of flight assays.
The FDA has granted Priority Review to the Biologics License Application (BLA) of belantamab mafodotin (GSK2857916; GlaxoSmithKline) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Progression-free survival, overall survival, and percentage of patients who achieved very good partial response or better were similar between both treatment groups.
The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
Bisphosphonate therapy is associated with renal toxicity.
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Patients with multiple myeloma may want to avoid consumption of foods associated with Listeria.
A putative mechanism of resistance to BCMA-directed CAR-T therapy involves BCMA antigen loss through cleavage of BCMA from the surface of myeloma cells.
“Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPI-0610.”
Long-term follow-up from the clinical trial investigating LCAR-B38M, a BCMA-targeting CAR-T, revealed that approximately three-quarters of patients achieved a complete response.
JNJ-4528 is a CAR-T therapy in which 2 antibodies against the B-cell maturation antigen BCMA are expressed on T cells.
This dose-finding study examined a bispecific antibody targeting BCMA and CD3 in patients with R/R multiple myeloma.
The presence of circulating tumor plasma cells by next-generation flow independently predicted disease progression after treatment in patients with multiple myeloma.
The detection of chromosomal aberrations in the main clone appear to have prognostic significance in patients with smoldering myeloma.
A retrospective analysis sought to determine the association between myeloproliferative neoplasms, MPN-directed therapy, and development of splanchnic vein thrombosis.
The TEAMM trial sought to assess time to first febrile episode or death from all causes in patients with newly diagnosed myeloma who received antibiotic prophylaxis vs those who did not.
Researchers explored a possible link between TNF-α and peripheral neuropathy in patients with MM treated with bortezomib.
The addition of plerixafor to treatment following transplantation may not enhance lymphocyte recovery in patients with multiple myeloma.
Uncertainty is defined in this study as “the inability to give sense or meaning to the processes or situations that have to do with medical conditions.”